Abstract
Robert Dreicer, MD, MS, MACP, FASCO, and Morgane C. Diven, PharmD, BCOP, discussed the emerging data regarding the role of genomics in metastatic castration-sensitive and -resistant prostate cancer, as well as strategies to manage the toxicities of current and emerging treatments for advanced prostate cancer.
